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ABSTRACT

Nicotine analogs that have nicotinic receptor antagonist
properties. These compounds have been shown to competi
tively inhibit dopamine release induced by nicotine. The
nicotine analog compounds are useful in the treatment of
nicotine abuse, smoking cessation therapy, as an antidote for
nicotine intoxication, treatment of cognitive disorders such

Janson, A.M. et al., “Chronic nicotine treatment decreases

as Alzheimer’s disease and for the treatment of Parkinson’s
disease.

dopamine D2 agonist binding in the rat basal ganglia.”
Neuroreport, V01. 3, No. 12, pp. 1117-1120, 1992.
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NICOTINIC RECEPTOR ANTAGONISTS IN
THE TREATMENT OF
NEUROPHARMACOLOGICAL DISORDERS

compositions. U.S. Pat No. 5,369,028 to Harpold et al.
discloses human neuronal nicotinic acetylcholine receptor
subunits.

FIELD OF THE INVENTION

for treating conditions responsive to nicotine therapy, and
for cessation of smoking therapy, by transmucosal admin

U.S. Pat. No. 5,362,496 to Baker et al. discloses amethod

istration of nicotine to a patient.

This invention relates to nicotine analogs that have nico

tinic receptor antagonist properties. The analog compounds

U.S. Pat. No. 5,316,759 to Rose et al. discloses a method

are shown to competitively inhibit dopamine release induced
by nicotine. The nicotine analog compounds are useful in the
treatment of nicotine abuse, smoking cessation therapy, as
an antidote for nicotine intoxication, treatment of cognitive

of treating and reducing a drug dependency such as a
nicotine dependency. The method involves administering
nicotine in an amount that would normally provide the
desired pharmacologic effects at a sustained level to partially
saturate the receptors in the subject to whom nicotine is
administered. An mecamylarnine is administered to block
the pharrnacologic effects of the nicotine.

disorders such as Alzheirner’s disease and for the treatment

of Parkinson’s disease.
BACKGROUND

U.S. Pat. No. 5,298,257 to Bannon et al. discloses a

The structure-activity relationship (SAR) of antagonist
molecules at neuronal nicotinic receptors have not been

systematically investigated. From the work that has been
reported, there appears to be far less correlation of structure

20

and function with antagonists than is observed with agonist
molecules (Barlow and Johnson, 1989a,b; Bears and Reich,
1970; Pauling and Petcher, 1973; Sheridan et al. 1986, 1987;
Wasserman et al. 1979). Due the diverse structures of
antagonist molecules, it is di?icult to propose a common

U.S. Pat. No. 5,187,169 to Lippiello et al. discloses
methods of treating neurodegenerative disorders such as
25

antagonist binding site or pharmacophore for receptor
antagonists such as lobeline, DHBI, neuronal bungarotoxin
and strychnine. Thus, it is possible that the noncorrelation of

Alzheimer‘s disease and Parkinson’s disease with an effec
tive amount of a cotinine compound
U.S. Pat. No. 5,069,904 to Masterson discloses a method

of using nicotine in the treatment of conditions susceptible
to such treatment. Such conditions include disease states

structure and function of antagonists may re?ect an antago

characterized by reduced central cholinergic function. Nico

nism at di?erent nicotinic receptor subtypes requiring spe
ci?c three dimensional antagonist pharrnacophores.

tine is administered to the subject until a therapeutic dose is
achieved.

Sheridan (1989) proposed that antagonists compete for
the same binding site as agonists; however, antagonists may
not bind in the same way as agonists. Furthermore, agonists
and antagonists may bind differently to di?erent quaternary

method of treating withdrawal symptoms associated with
smoking cessation with transdermal delivery of nicotine.
U.S. Pat. No. 5,232,933 to Lippiello et al. discloses
treating neurodegenerative diseases with an eifective
amount of an alpha-nicotine type compound.

NeumReport, Vol. 3, No. 12, pp. 1117-1120, December
35

1992, discloses chronic nicotine treatment decreases dopam
ine 2 agonist binding in rat basil ganglia.

states of the receptor protein. However, it is presumed likely

The European Journal of Pharmacology, Vol. 173, No. 1,

from the data available that both agonists and antagonists are

pp. 93-108, Nov. 28, 1989, set out to determine whether
N-methylcarbicol acts as an agonist or antagonist at nicotine
and/or mnscarinic receptor sites. Nicotine stimulates the
release of [3H]dopamine from rat striatal synaptosomes

recognized by the anionic and donor groups in the binding
site. One must assure that some property other than phar

macophore geometry must be important for antagonism.

pre-loaded with dopamine.

Sheridan et a1. (1989) suggested that to be an agonist, a
molecule must not only be able to achieve the pharmacoph

The Journal of Neurochemistry, Vol. 46, No. 4, pp.

ore geometry, but must also be con?ned to a speci?c volume.
1109-17, April 1986 discloses that acetylcholine and nico
Nicotine compounds and derivatives are known. For 45 tine accelerated the basil out?ow of gamma-arninobutyric

acid (GABA) from rabbit caudate nucleus. ‘The ?ndings

example, U.S. Pat. No. 4,965,074 to Leeson discloses a
method for the treatment of memory impairment, especially

indicate that the GABA neurons and the caudate nucleus

senile dementia of the Alzheimer's type. Nicotine is one

may be stimulated by dopamine and stimulated by acetyl

compound.

choline via a nicotine receptor.

U.S. Pat. No. 5,227,391 to Caldwell et al. discloses a

method of treating neuro-degenerative diseases by admin
istering an effective amount of R(+) nicotine. U.S. Pat. No.
5,272,155 to Arneric et al. discloses a (+)2-methylpiperidine
which is a speci?c modulator of the neuronal nicotinic
cholinergic receptor and which is useful in the treatment and

prevention of cognitive, neurological and mental disorders.
U.S. Pat. No. 5,278,176 to Lin discloses selective potent
nicotinic agonists which are useful in the treatment of

55

The Journal of Neurochemistry, Vol. 40, No. 4, pp.
1106-9, April 1983 disclosesthat tetrodotoxin-sensitive Na+
channels block nicotine transmission, possibly by noncom
petitively inhibiting the interaction of nicotine with the
receptor binding site.
Biochemishy, Vol. 19, No. 12, pp. 2770-9, Jun. 10, 1980,
describes the quantitative analysis of nicotine acetylcholine
receptor function in torpedo postsynaptic membranes.
Biochemistry Soc. Symp., Vol. 59, pp. 83-95, 1993 ,

dementias, attentional hyperactivity disorder, anxiety asso

discloses a view among researchers and clinicians that

ciated with cognitive impairment, or substance abuse with
drawal. U.S. Pat. No. 5,276,043 to Lippiello et al. discloses

habitual cigarette smoking is a form of dependence on
nicotine. It is the central action of nicotine that appears to be

treatment of patients suffering from negrodegenerative dis

particularly important in this regard. Although multiple

eases with an effective amount of an unsaturated nicotine

subtypes of nicotine receptor are expressed in the brain,
attention has focused on a prevalent subtype (containing
alpha 4 and beta 2 subunits) which is believed to represent
the prime target for “smoking doses” of nicotine. The
mesolimbic dopamine system, a neuronal population which

compound Alzheimer’s disease and Parkinson’s disease are
speci?cally mentioned as neurodegenerative disorders.
U.S. Pat. No. 5,371,188 to Heinemann et al. discloses a

family of neuronal nicotinic acetylcholine receptor subunit

5,691,365
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has been implicated in the reinforcing actions of certain
drugs (e.g. amphetamine), also appears to mediate the rein
forcing actions of nicotine in laboratory rats. Pharmaco
therapeutic approaches to smoking cessation rely on nicotine
replacement. This publication argues that the administration

I

of a selective antagonist of central nervous system nicotine

10

carbon atoms, and N-a1kynyl or branched alkynyl with 2-19

carbon atoms. X=Cl", Br‘, 1“, H804“, 1AS042‘. These

of nicotine, the receptor binding and psychotropic properties

compounds are useful in the treatment of nicotine abuse,
smoking cessation therapy, as an antidote for nicotine
intoxication, treatment of cognitive disorders such as Alzhe
imer’s disease and for the treatment of Parkinson’s disease.
It is another object of the invention to provide compounds

of nicotine agonists and antagonists, and the neuroanatomi
cal locus of action of nicotine associated with its psycho

tropic action. Bridged analogues of nicotine have been
developed to de?ne the optimal conformation of the mol
ecule for maximal receptor a?inity and psychotropic action

having nicotinic receptor antagonist properties.
In a preferred embodiment the invention provides A

in rats. With another series of analogues, it was demon
strated that contraction of the pyrrolidine ring to a 4-member

Neuroendocrinology, Vol. 47, No. 4, pp. 303-8, April
1988, discloses the e?tect of cholinergic agonists and antago

wherein R=N-alkyl or branched alkyl with 2-19 carbon

atoms, cycloalkyl, aralkyl, N-alkenyl or alkenyl with 2-19

The Journal of Substance Abuse, Vol. 1, No. 3, pp.
259-71, 1989, describes dealing with the molecular features

azetidine enhances potency while expansion diminishes it. A
major site for nicotine’s central action is the vestibular
cerebellum as demonstrated by kainic acid lesioning studies
and direct administration of nicotine into this region.
Included among the antagonists to nicotine was alpha
lobeline, which appeared to be a mixed agonist-antagonist.

l

CH3

ti‘
CHg-R

receptors may lead to higher long-term abstinence rates, and
research strategies for the development of such a drug are
outlined

/

method of antagonizing the nicotinic receptor comprising

25

administering a pharmaceutically effective amount of a
compounds of the invention.
In still another embodiment the invention provides a
method of treatment of nicotine abuse, as smoking cessation
therapy, as an antidote for nicotine intoxication comprising
administering a pharmaceutically e?’ective amount of a

compound according to the invention.
30

Advantageously the invention provides a method of treat
ment of treatment of cognitive disorders selected from the
group consisting of Alzheimer’s disease and Parkinson's

nists on rat hypothalamic and corticotropin-releasing hor

disease comprising administering a pharmaceutically effec

mone secretion in vitro. Acetylcholine (ACh) stimulated

tive amount of a compound according to the invention.

hypothalamic IR-rCRH secretion in a dose-dependent
fashion, at concentrations ranging from 3.3X10(—10) to
10(—5)M. This elfect was antagonized by the simultaneous

The above and other objects of the invention will become
readily apparent to those of skill in the relevant art from the

following detailed description and ?gures, wherein only the
preferred embodiments of the invention are shown and

presence of atropine and hexamethonium, a muscarinic and

described, simply by way of illustration of the best mode of
carrying out the invention. As is readily recognized the

a nicotinic receptor antagonist, respectively (p less than
0.05). Further evidence for the cholinergic regulation of the
CRH neuron was provided by the ?ndings that both
carbachol, a muscarinic receptor agonist, and nicotine, a
nicotinic receptor agonist, stimulated IR-rCRH secretion in
a dose-dependent fashion. These eifects were antagonized

by atropine and hexamethonium, respectively, suggesting

invention is capable of modi?cations within the skill of the
relevant art without departing from the spirit and scope of
the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
45

that both muscarinic and nicotinic receptors are involved in
the process.

The nicotine analogs of the present invention have not
been disclosed by any prior art and unexpectedly have
di?’erent properties than known compounds. The present
nicotine analogs that have nicotinic receptor antagonist
properties. The analog compounds are shown to competi
tively inhibit dopamine release induced by nicotine. The
nicotine analog compounds overcome the de?ciencies of

50

55

pounds studied in [3H]DA release assays. Abbreviated
nomenclature is given in parentheses.
FIG. 2 shows IC50 values for N-substituted analogues of
nicotine, nornicotine, and cotinine to inhibit nicotine-evoked
[3H]DA release from rat striatal slices.
FIG. 3 shows space ?lling models of minimum energy
conformers of N'-protonated S(—)nicotine and the unproto
nated and protonated forms of NONI.
FIG. 4 shows overlay of the minimum energy conformers

of protonated S(—)nicotine (red) and unprotonated S(—)
NONI (black) showing the comparable N-N‘ intra-atomic

prior art compounds and are useful in the treatment of
nicotine abuse, smoking cessation therapy, as an antidote for

distances in these molecules and the hypothetical mode of
binding at the anionic site (A) and the hydrogen donor site
(B) of the nicotinic receptor.

nicotine intoxication, treatment of cognitive disorders such
as Alzheimer’s disease and for the treatment of Parkinson’s

disease.

DESCRIPTION OF THE INVENTION
DISCLOSURE OF THE INVENTION
65

The invention provides compounds of the following for
mula:

FIG. 1 shows structures of S(—)nicotine and related com

The present nicotine analogs have nicotinic receptor
antagonist properties. The analog compounds are shown to
competitively inhibit dopamine release induced by nicotine.
The nicotine analog compounds overcome the de?ciencies
of prior art compounds and are useful in the treatment of

5,691,365
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nicotine abuse, smoking cessation therapy, as an antidote for
nicotine intoxication, treatment of cognitive disorders such

pletely block nicotine‘s e?’ect. Furthermore, NONI did not

as Alzheirner’s disease and for the treatment of Parkinson’s

possess agonist activity at concentrations which completely
blocked nicotine-evoked [3H]DA release. The pKa values

disease.

determined for S(—)nicotiue and one of the most active

.

Hybridization cloning has revealed a surprising degree of 5 antagonists, S-N-allyl-nicotinium iodide (NANI), shows
that these analogues exist predominantly in their unproto
subtype diversity among neuronal nicotinic receptors
nated form at physiological pH.
(Leutje et al. 1990a; Deneris et al. 1991); Role, 1992;
Molecular modeling studies suggest that these antagonists
Sargent, 1993). There are two types of neuronal nicotinic
subunits 0t and [3. The on subunits are identi?ed by a pair of

adjacent cysteine residues in the amino terminal domain and

10

nicotine with this receptor. This structure-activity data pro
vides useful information on the antagonist pharmacophore
of the nicotine receptor subtype responsible for modulation
of dopamine release from presynaptic terminals in the brain.
Thus, it is proposed that these antagonists bind to the
receptor in their nnprotonated forms and that the binding‘
mode involves interaction of the quaternary pyridinium-N
atom with the anionic site of the receptor. The unprotonated

are traditionally thought of as the agonist-binding subunit.

Eight subtypes of the ot subunit (0t2-0t9) and three subtypes
of the {5 subunit (52-154) have been found in the vertebrate
nervous system. The functional signi?cance of this subtype
diversity is still a mystery.

,

Both native and cloned subtypes are pharrnacologically
distinct in their response to both nicotinic agonists and

antagonists. In terms of antagonists, ot-bungarotoxin
(ot-BTX) selectively blocks receptors that contain the 0L7,
0L8, or (19 subunits, and neuronal bungarotoxin (NBTX)
selectively blocks the (1362 receptor (Leutje et al. 1990b).

20

However, there are no selective toxins for receptors that

contain the 0L2, 0L4, or [34 subunits.
Nicotine activates presynaptic neuronal nicotinic recep
tors evoking the release of dopamine (DA) from presynaptic
terminals in the central nervous system (Giorguieif

may interact with the nicotinic receptor in a novel binding
mode which is diiferent from the mode of interaction of

pyrrolidine-N atom serves as the hydrogen bond acceptor,
which reverses the roles the nitrogens normally play in the
binding of nicotine to the receptor. The N-alkyl substituent
most likely binds to a site that extends beyond the normal

agonist pharrnacophore volume which may prevent the

receptor protein from achieving its open-channel quaternary
25

form.
Thus, a new class of e?icacious nicotinic antagonists have

Chesselet et al. 1979; Westfall et al. 1993; Rowell et al.

been discovered which inhibit nicotine evoked [3H]DA

1987; Rapier et al. 1988, 1990; Grady et a1. 1992). The
speci?c nicotinic receptor subtype which mediates nicotine

release from dopaminergic nerve terminals in the brain
providing new tools for unraveling the role of neuronal

evoked DA release has not been directly identi?ed, but has

30

been suggested to be the (13132 subtype (Schulz et al. 1989;

nicotinic receptors modulating dopamine release. A descrip
tion of synthesis methods for these compounds, their phar

Grady et al. 1992). Developing subtype-selective antago

maceutical formulations and their methods of use are set

nists are particularly important, because there are no selec

forth below.

tive toxins for receptors that contain the 0t2, 0t4, or [54

subunits. Furthermore, development of subtype selective 35
antagonists for the 01352 subtype is important, because
NBTX is practically unavailable due to export restrictions
on the source snakes.

(Tables 2 and 3). Compounds IVA-G were synthesized via
direct alkylation of the pyridine-N atom of S(—)nicotine
following a modi?cation of the method reported by Shiba
gaki et a1. (1982). Compound V was synthesized by the
45

from racemic nornicotine via the reported method of Pool

(1987). Compound VIB was prepared by reaction of racemic
nornicotine with allyl iodide (Table I). All products were
characterized by elemental analysis which afforded values
that did not deviate by 10.40% of theoretical values, and by
1H-NMR. The 1H-NMR spectra of compounds IVA-G were
consistent with alkylation occurring at the pyridine-N atom

Structure-activity relationships indicate that the order of
potency correlated with increase in alkyl chain length.
Introduction of an aromatic or unsaturated residue into the

pyridino-N substituent also afforded compounds with sig

(NONI).
NONI had a potency approximately half that of the

classical nicotinic antagonists, mecamylamine and dihydro

method of McKennis et al. (1963), and compound VII was

synthesized using a modi?cation of the method employed by
Seeman and Whidby (1976). Compound VIA was prepared

cacious analogues were those that contained a pyridino
N-alkyl substituent of three carbons or more in length.

ni?cant antagonist activity. The most e?icacious and potent
compound in the series was S-N-octylnicotinium iodide

Synthesis. Several N-substituted analogues of S(—)
nicotine (I), S(—)cotinine (I1) and racernic nornicotine (III)
were prepared (FIG. 1 and Table 1) and evaluated for their
ability to act as antagonists at neuronal nicotinic receptors

The invention relates to the development of novel nico

tinic antagonists which inhibit nicotine-evoked dopamine
release from rat striatal slices, with selectivity at the 013B2
neuronal nicotinic receptor subtype.
A series of N-substituted nicotine analogues were synthe
sized and evaluated for their ability to inhibit nicotine
evoked [3H]dopamine([3H]DA) release from rat striatal
slices. Of the eleven compounds examined, the most e?i

EXAMPLE 1

55

rather than at the pyrrolidine-N atom, as indicated by the
down?eld chemical shift values for the aromatic protons
compared to the values for the same protons of nicotine. The
pyrrolidine N-methyl group exhibited a similar chemical

[i-erythroidine (DHBE). Moreover, NONI completely

shift (approximately 2.3 ppm) for the NCH3 singlet in both

blocked the effect of nicotine to evoke [3H]DA release,
whereas the classical antagonists inhibited but did not com

nicotine and nicotine analogues IVA-G. Synthetic and ana
lytical data for the above compounds is provided in Table 1.

5,691,365
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TABLE 1

Surihetic and anal?ical data for N-substituted nicotine analoggs
Compound’

Reaction

Reaction

Reaction

%

R

X

Solvent

Temperature

Tune

Puri?cationb Yield Point (°C.)

Melting

AcOH
AcOH .

re?ux
ambient

12 h
48 h

A
B

S-IVa
S-IVb

NMNI
NPNI

H
CH2CH3

II-

75
56
64
40
20
65

165-166
83-84
88-90
81-82
oil
159-160

S-IVC
S-IVd
s- Ve
S-IVf

NAN]
NnBNI
NONI
NBNB

S-IVg

NHEN'I

CH=CH2
(C]-l¢)2CI-[3
(crrzkcrr,
C611,
CH2OH

IIrBrI-

AcOl-l
MeOH
MeOH
AcOH
MeOl-I

ambient
+55° C.
+ss° c.
+55° C.
+55° C.

48 h
48 h
48 h
24 h
48 h

B
ehromatogr.
B
B
chromatogr.

S-V

N'MCI

—

I-

MeOH

+50‘7 C.

3 h

C

79

55

hygroscopic
147-148

(:t:)VIa
(i)Vl'b

NT-IIN'NI
DNANI

Rl=CH3;R2=H
Rl=R2dCH2CH=CH3

II-

AcOH
THF

ambient
ambient

24 h
24 h

D
B

67
55

207-209
123-124

S-VH

PIPNNN

—

I-

MeOH

ambient

24 h

D

60

135-137

‘See Figure 1 for structures of compounds.
"Metlnd of Puri?cation: A, After evaporation of the solvents and addition of sat'ln'ated Nail-[C03, the basic solution (pl-I = 8) was
washed with other before extraction with chloroform. B, Column chromatography over silica gel elution with 5% MeOH in

chloroform. C, Recrystalization from MeOH. D, Preparative cation-exchange H'PDC.

pKa Determination. A solution [1 g in 12 rnls of deuterium
oxide 100% atom D] of the compound under investigation
was gradually acidi?ed by drop-wise addition of a solution
of DC1 to D20 (20% wt/wt, 99.5% atom D). The pD values

bated for 30 min in Krebs’ buifer (in nM; 118 NaCl, 4.7 KCl,

1.2 MgCl2, 1.0 NaH2P04, 1.3 CaCIQ, 1.3 CaClz, 11.1
25

were measured on a Corning pH meter. For each pD value,
a sample (0.8 rnls) was analyzed by 1H-NMR on a Varian

a metabolic shaker at 34°. Slices were rinsed with 15 ml of
fresh buffer and incubated for an additional 30 min in fresh

Unity 300 MHz spectrometer using sodium 3(nimethy1silyl)
-2,2,33-d4-propionate (TSP) as internal reference. Protona
tion of the pyrrolidine- and pyridine-N atoms was followed
by observing the variation in chemical shift of the N-1'
methyl and 2‘-proton signals from p0 8.8 to pD 3.0. A
titration curve of pD vs chemical shift was constructed to

buffer containing 0.1 pM [3H]dopa.mine (6 slices/3 ml).
30

superfused (1.0 ml/min) for 60 min with Krebs’ buifer

maintained at 34° C., pH 7.4 with continual aeration (95%
35

Subsequently, S(—)nicotine (10 M) was added to the buffer

each pD value, a sample (0.8 rnls) was analyzed by 1H-NMR

and an additional 12 consecutive 5-min samples were col
lected. At the end of the experiment each slice was solubi
lized and the [3H] content of the tissue determined.

on a Varian Unity 300 MHZ spectrometer using sodium

3-(trimethylsilyl)-2,2,33-d4-propionate (TSP) as internal
reference. Protonation of the pyrrolidine- and pyridine-N

shift of the N-l'methyl and 2‘-proton signals from pD 8.8 to

45

pD 3.0. A titration curve of pD vs chemical shift was

constructed to determine the pKa values of pyrrolidino-N
atom and/or the pyridine-N atom.

Computational Chemistry. The molecular modeling pack
age HYPERCHEM© (AutodesK, Inc. California) was used
to calculate energy-minimized conformers of protonated and
unprotonated molecules. Partial charges were calculated
using External Hiickel Methods, and structures were ruini
rnized with the MM+ molecular mechanics force ?eld, using
Polak-Ribiere as the minimization algorithm,

50

release for each superfusate sample was calculated by divid
ing the total tritium collected in each sample by the total
tritium present in the tissue at the time of sample collection.
Basal [3H]out ?ow was calculated from the average of the
tritium collected in the two 5-min samples just before
sure to the test compound or exposure to nicotine in the

55

absence and presence of the test compound equaled total

[3H]over?ow. [3H]over?ow was calculated by subtracting
the [3H] out?ow during an equivalent period of prestimula
tion from the values in samples collected during and after
drug exposure. Inasmuch as the radiolabelled compounds

g) were obtained from Harlan Laboratories (Indianapolis,
Ind.) and were housed two per cage with free access to food
and water in the Division of Lab Animal Resources at the

were not separated and identi?ed, the tritium collected in
superfusate is referred to as either [3H]out?0w or [3H]

College of Pharmacy at the University of Kentucky. Experi
mental protocols involving the animals were approved by

over?ow, rather than as [3H]DA. [3H]Over?ow primarily
represents [3H]DA in the presence of nornifensine and
pargyline in the superfusion buffer (Zumstein et a1. 1981).

the Institutional Animal Care and Use Committee at the

University of Kentucky.
[3H]DA Release Assay. Rat striatal slices (500 um

Radioactivity in the superfusate and tissue samples was

determined by liquid scintillation spectroscopy. Fractional

addition of the N-substituted nicotine analogue. The sums of
the increase in collected tritium resulting from either expo

Biological Methods. Male Spragua-Dawley rats (150-200

thickness, 6-8 mg wet weight) were obtained as previously
described (Dwoskin and Zahniser, 1986). Slices were incu

O2/5% C0,). rIwo 5-min samples (5 ml) were collected to
determine basal out?ow of [3H]DA. N-Substituted nicotine
analogues were added to the superfusion bu?’er after the
collection of the second sample and remained in the butfer
until 12 consecutive S-min samples were collected.

'Ihe pD values were measured on a Corning pH meter. For

atoms was followed by observing the variation in chemical

Subsequently, slices were rinsed with 15 ml of fresh bu?’er
and transferred to a glass superfusion chamber. Slices were

containing nomifensine (10 pm) and pargyline (10 pm) and

determine the pKa values of pyrrolidino-N atom and/or the
pyridine-N atom.
Computational Chemistry. A solution [1 g in 12 rnls of
deuterium oxide 100% atom D] of the compound under
investigation was gradually acidi?ed by drop-wise addition
of a solution of DC1 to D20 (20% wt/wt, 99.5% atom D).

glucose, 25 NaHCO3, 0.11 L-ascorbic acid nd 0.004 diso
dium EDTA; pH 7.4 and saturated with 95% O2/5% CO2) in

65

The effects of the nicotinic agonist, S(—)nicotine, and two

of its metabolites, S(—)cotinine and (i)nornicotine, on [3H]
DA release from rat striatal slices are shown in Table 2.
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TABLE 2

DI-[BE and rnecamylmine, had any signi?cant eifect on
[3H]DA release in the concentration range of 1-10 11M.

However, at the highest concentration (100 PM) examined,
HONI, NBNB, and (i)NMNNI evoked [3H]DA release and
thus, possess intrinsic agonist activity at this concentration.

TABLE 2. The e?ect of S(—)nicotine, S(—)cotinine, S(—)cytisine
and racernic nomicotine on 135 EA release from rat striatal slices

In particular NONI was quite e?icacious and exhibited

Concentration 1M]
Compound

N‘

1

10

100

S(—)nicotine
S(—)cystisine
S(—)ootinine
(i)norniootine

9
5
6
8

2.80 i 0.28"
0.67 i 0.26
0 i: 0
1.40 :t 0.24

3.24 i 0.37
0.85 i 0.38
1.14 i 0.36
2.60 i 0.38

5.56 i 0.50
1.13 i 0.46
2.06 :l: 0.35
4.20 i 0.34

three-times the agonist activity of nicotine at the 100 |.|M
concentration. At this high concentration, DHBE also

evoked [3H]DA release (Table 3).
10

The N-substitnted nicotine analogues were evaluated for

their ability to inhibit nicotine-evoked [3H]DA release

(Table 4).

‘N = number of animals.

TABLE 4

"Data are expressed as total [al-?over?ow, mean i SEM.

N-Substituted nicotine analogue-induced antagonism of
S(—)nicotine (l0 pM)-evoked [3H]DA release from rat

The effect of the high a?inity nicotinic ligand, S(—)
cytisine, was also evaluated for its ability to release [3H]DA
from striatal slices. From these data, S(—)nicotine produced
a concentration-dependent increase in [3H]DA release and
was the most potent and e?icacions compound compared to
the other agonists studied. Racemic nornicotine also pro
duced a concentration-dependent increase in [3H]DA
release, but evoked release which was only 50% of the effect

produced by S(—)nicotine at 1 M, and approximately 80%
of that at the higher concentrations. The effect of racemic
nornicotine was compared with that of S(—)nicotine because
of the reported lack of stereoselective e?ect of nornicotine
(Reavill et a1. 1988; Copeland et a1. 1991; Risner et al. 1985,
1988; Goldberg et al. 1989) and due to the di?iculty in

obtaining enatiomerically pure forms of nornicotine.
Cotinine, the major metabolite of nicotine, had no effect at

1 pM, and only produced a small effect (35% of nicotine’s
e?ect) at the higher concentrations.
The N-substituted nicotine analogues described in Table 1
were evaluated for their ability to evoke [3H] release from
rat striatal slices at three concentrations (1, 10 and 100 pM)

striatal slices

__.—®11s=_m_ti°atM)__—
20 Com
pound
NONI
DHBE
NBC
25 N'BNB
NPNI
NnBNI
NANI
NHEN'I
(i)
DNANI
(i)
NMNNI
NMNI

NMCI
PIPNMN

N‘

0c

1

10

100

6
5
4
7
8
5
9
6
5

1.84 i 0.201: 1.21 :t 0.14
3.10 i 0.60 1.59 i 0.09
2.64 i 0.84 0.87 :1: 0.18
2.98 i 0.51 1.50 :t: 0.55
2.06 i 0.45 1.63 :t 0.41
2.3 i 0.41 2.70 i 0.52
1.96 i 0.29 2.61 i 0.46
2.45 :l: 0.40 1.66 i 0.10
1.94 i 0.39 2.58 i 0.54

0.03 :t 0.02
0.73 i 0.12
0.68 t 0.23
1.27 i 0.35
0.88 :l: 0.51
1.03 i: 0.28
0.92 i 0.35
2.13 i 0.38
1.85 i 0.25

NDd
ND
0.41 :l: 0.31
ND
0.31 :i: 0.13
0.39 i 0.09
0.48 i 0.18
0.34 i 0.11
1.66 :1: 0.36

5

2.97 i: 0.48

2.22 i 1.26

3.53 i 0.85

ND

5
5
4

1.94 i 0.29
2.97 i 0.48
3.07 :i: 0.61

2.10 i 0.81
3.11 i: 1.32
3.16 i 1.46

3.33 i 1.27
3.11 i 1.20
2.98 i 1.48

1.65 i 0.90
3.75 i 1.66
1.88 :t 0.77

35 N“ = number of animals.
'’Data are expressed as total [3H]over?ow, mean i S.E.M. during

(Table 3).

co-superfusion with 10 1.1M nicotine.
°Nicotine (10 uM)-evoked total [al?over?ow determined for each experi
ment. Grand mean was 2.52 :t 0.12 with a range of 1.03-4.65 for N = 82

TABLE 3

awnpiim

as a result of intrinsic agonist activity.

The elfect of DHBE, MEC and N-substit'uted nicotine
analo

s on

In these experiments, the striatal slices were superfused for
60 min with various concentrations of the analogues prior to

DA release from rat striatal slices

Concentration 1 M]
Com
potmd

N‘ 0

1

10

nicotine (10 pM) exposure. Antagonist activity was evalu
ated by comparing the nicotine-evoked [3H] over?ow in the
100

45

absence and presence of the analogues. From the group of

quaternary ammonium analogues examined, PIPNMN,
NONI
DHBE
NBC
NBNB
NPNI
NnBNI
NANI
NHENI
(It)
DNANI
(i)
N'MNNI
NW1
NMCI
PIPN'MN

6
5
4
7
8
5
9
6
5

0.01 :t: 0.011’
0.00 :t 0.00
0.00 i 0.00
0.05 i 0.05
0.00 :1: 0.00
0.00 i 0.00
0.00 :l: 0.00
0.10 i 0.07
0.02 i 0.01

0.03 :1: 0.02
0.02 :t: 0.02
0.00 i 0.00
0.21 i 0.12
0.06 i 0.01
0.00 i 0.00
0.02 i 0.02
0.00 i 011)
0.02 i 0.01

0.14 i
0.36 i
0.00 :i:
0.28 i
0.03 i
0.01 i
0.07 i
0.00 :1:
0.08 i

0.14
0.22
0.00
0.12
0.03
0.01
0.04
0.00
0.04

16.4 :1: 2.00
2.01 :k 0.28
0.00 i 0.00
6.04 i 0.97
0.03 i 0.03
0.01 i 0.01
0.08 i 0.03
0.08 i 0.04
0.00 :t 0.00

50

5 0.00 i: 0.00

0.17 i 0.11

0.01 i 0.01

2.60 i 0.38

55

5 0.02 i 0.01
5 0.00 :t 0.00
4 0.00 d: 0.00

0.13 i: 0.11
0.00 i 0.00
0.03 i 0.03

0.17 i 0.10
0.01 i: 0.01
0.01 i 0.01

0.08 i 0.06
0.02 :i: 0.01
0.05 i 0.02

N‘ = number of animals.

t’Dat:a are expressed as total [311] over?ow, mean i S.E.M.

In addition, the classical competitive and noncompetitive
nicotinic antagonists, DHBE (Vidal and Changeux, 1989;
Alkondon and Albuquerque 1991; Mulle et a1. 1991) and
mecamylamine (Grenhoff and Svensson, 1989; Mulle et a1.
1991) were also examined in this assay for the sake of

comparison. None of the compounds examined, including

NMCI, NMNI, (i)NMNNI, and (i)DNANI did not exhibit
signi?cant nicotinic antagonist activity over the concentra
tion range tested. However, it should be noted that two of
these inactive compounds are racemates. Signi?cant antago

nist activity was observed with NHENI, NANI, NnBNI,
NPNI, NBNB and NONI. The relative order of potency of

the classical and pyridine-N substituted nicotine analogues
for inhibition of nicotine-evoked [3H]DA release from rat
striatal slices is illustrated in FIG. 2 by a comparison of their
IC50 values. The order of potency wherein NONI>>DIIBE=

MEC>>NBNB=NPNI=NnNBI=NANI>NHENI>>>(i)di
N-allyl nicotiniurn iodide (DNANI)=(i)N-methyl nornico
tinium iodide (NMNN'I)=NMNI=S-N-methyl cotininium

iodide (NMCI)=S-N‘-methyl nicotinium iodide (PIPNMN).
The most potent and e?icacious antagonist in this series of
analogues was clearly NONI (Table 4 and FIG. 2). At the
low concentration of 10 PM, NONI completely inhibited
nicotine-evoked [3H]DA release. Furthermore, NONI was
65 16-fold more elfective than DHBE and MEC at this con

centration. However, the NONI-induced inhibition of the
etfect of nicotine could not be determined at the 100 pM,
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since similar to DHBE, NONI possessed intrinsic agonist
activity at this high concentration. It is important to note,
however, that the intrinsic agonist activity of NONI was
observed at a concentration 10-fold higher than that required

S(—)Cotinine, the major metabolite of S(—)nicotine
detected in brain (Petersen et al. 1984); Stalhandske, 1970)
had little etfect even at high concentrations in the DA release

assay. Interestingly, the high ai?nity ligand S(—)cytisine only

to completely inhibit nicotine-evoked [3H]DA release.
Determination of the pKa value of the pyrrolidino-N
functionality of NANI by H-NMR analysis a?orded a value
of 6.4 This value for NANI was considerably lower than the
pKa value of 8.4 for the same functionality in the nicotine
molecule when analyzed in ‘an identical manner. The

pyridine-N functionality of nicotine afforded a pKa value of
3.75. These results indicate that at physiological pH (7.6) the
quaternary nicotine analogues exist predominantly in their
unprotonated forms whereas, nicotine exists predominantly

marginally released dopamine from the stn'atal slice, pro

10

ducing approximately 20% of the etfect of nicotine at each
concentration examined in the present study. These results
are in agreement with others (El-Bizri and Clarke, 1994)
reporting a lesser e?’ect of cytisine compared to nicotine in
evoking dopamine release from rat striatal synaptosomes.
The results suggest that the nicotinic receptor subtype modu
lating DA release may be dilferent from nicotinic receptor

subtype(s) that avidly bind [3H]nicotine and [3H]cytisine.
Unexpectedly, DHBE, the competitive nicotinic

in its N- 1‘ protonated form. Thus, both molecules are mono

antagonist, evoked [3H]DA release at the highest concen
tration examined (Table 3). This etfect has not been previ
ously reported. It is doubtful whether concentrations of
DHBE as high as 100 PM have physiological relevance in

cationic at physiological pH, but the positive charge in the
respective molecules is located on diiferent nitrogen atoms.
Conformational analysis data for nicotine and the three
most effective antagonists provides information on the

energy-minimized conformations of the protonated and

vivo. Nevertheless, this concentration of DHBE is used

unprotonated forms of these compounds (‘Table 5).

routinely for nicotinic receptor antagonism in in vitro phar
macological studies (Grady et al. 1992; El-Bizri and Clarke,

1994).

TABLE 5

From structure-activity considerations of the series of
Table 5. Characteristics of

‘

'

energyconform ations

'
ammonium
analo -

for

nicotine analogues examined, it is evident that quaterniza

sofnicotine

25

N—N' Inna-atomic Distance

Torsion Angle

(Ansstmm)

(Dames)

free base

4.35

109.8

nnmprotonated (N""H)
diprotonated

4.19
4.70

113.2
117.0

comwmd

tion of the pyridine-N atom of S(—)nicotine can result in

compounds that possess antagonist activity in the nicotine
evoked [3H]DA release assay. Greatest antagonist potency

C(3)-4J(2')

was obtained with an pyridine-N substituent (NONI) bearing
eight carbons in a linear chain. Smaller carbon chains (two

Nicotine
30

to ?ve) had signi?cantly lower potency and e?icacy (i.e.,
NANI, NPNI, NnBNI, and NBNB). Consistent with this
trend in structure activity is the ?nding that introduction of

a sterically small pyridine-N substituent atfords an analogue,

NBNB

NMNI which exhibits no antagonistic activity. Similarly,
monocation

4.04

112.2

dicntion (N"‘H)

4.90

115.7

35

NANI

pyridino-N-methylation of both S(—)continine and
(i)nornicotine also aiforded compounds (NMCI and NMNI,
respectively) which were devoid of antagonist activity.
Pyridine-N quaternization of a nicotine analogue in which

nnmcation

4.00

111.4

dication (Nl‘H)

4.81

117.7

the pyrrolidine-N-methyl group has been substituted by a

larger alkyl group (i.e., N-allyl, see (i)DNANI) results in
relatively weak antagonist activity compared to the N-allyl
nicotine analogue (NANI).

NONI
monocation

4.08

111.2

dicntion (1W1!)

4.70

116.8

Introduction of unsaturated or aromatic moieties into the

As expected, generation of a dicationic species of these
compounds results in a signi?cant change in the N-N‘

pyridine-N substituent structure also results in compounds
45

positive nitrogen centers, which induces a signi?cant rota
tion about the C(3)-C(2') bond. Since the NMR data indi
cates that it is predominantly the monocationic form of the
antagonist that exists at physiological pH, it is likely that this
is the form that interacts with the nicotinic receptor. It is
interesting to note that the N-N' intra-atomic distance and
the C(3)-C(2') torsion angle value for the monocationic (i.e.,
unprotonated) forms of the antagonist molecules‘ corre
sponds quite closely to the same values for the monoproto

possessing antagonist activity (e.g., NANI nd_ NBNB,
respectively). Thus, a relatively-long, linear, alkyl chain

intra-atomic distance as compared to the monocationic spe
cies. This is due to the charge repulsion between the two

representing a substituent that is lipophilic in nature appears
to be an important determinant of antagonist activity in these

quaternary ammonium analogues of nicotine. Antagonists
50

are almost always large molecules, which, if docked onto the
agonist, would extend outside the normal against volume.
Thus, the extra bulk associated with the antagonist structures

may prevent the receptor protein from achieving the open
channel quaternary form.
55

nated S(—)nicotine species.
As has been previously reported (Giorguie?-Chesselet et

The inventors show the molecules described are binding
to the antagonist site in their unprotonated forms and that the
binding mode involves interaction of the quaternary ammo
nium nitrogen with the anionic site of the receptor. The

al. 1979; Westfall et al. 1983; Rowell et al. 1987; Rapier et

unprotonated tertiary amine (i.e. the pyrrolidine N) interacts

al. 1988, 1990; Grady et al. 1992; Dwoslcin et al. 1993),

with the hydrogen-bond donor site. This is the reverse of the
normal binding mode of an agonist such as nicotine (FIG. 3).

nicotine and nornicotine evoked a concentration-dependent
increase in [3H]D'A release from rat striatal slices; however,
nornicotine was less potent in producing this effect. In the
current study, the ECSO value for nicotine was=2 M, which
is within the wide range of ECSO values (10 nM-lO pM)

reported by others (vide supra) using various preparations
and nicotine exposure times.

‘The pKa values for the quaternary nicotine analogues is in
accord with this hypothesized mode of binding, since it
' clearly indicates that the most predominant species of the
65

quaternary ammonium nicotine analogue at physiological
pH is the unprotonated form; whereas in the case of S(—)
nicotine, the most predominant form at this pH would be the

5,691,365
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pyrrolidine-N protonated form. The locus of positive charge

to humans and animals in unit dosage forms, such as tablets,

is thus switched from one nitrogen to the other in these two

capsules, pills, powders, granules, suppositories, sterile

structures.

parenteral solutions or suspensions, sterile non-parenteral
solutions or suspensions oral solutions or suspensions, oil in
water or water in oil emulsions and the like, containing
suitable quantities of an active ingredient

The molecular modeling data on the three most active

antagonists NANI, NONI and NBNB, provide the two
pH-dependent, energy-minimized conformations in aqueous
solution. The unprotonated species of NONI, the most active

Topical application can be in the form of ointments,
creams, lotions, jellies, sprays, and the like. For oral admin

antagonist, in which the N-N‘ atomic distance is about 4.0 A
is illustrated in FIG. 3. The N'-protonated species of this
compound (FIG. 3) has an N-N' atomic distance which is

prepared with the compounds of the invention. The com

signi?cantly greater than 4.0 A in its preferred conformation.

pounds are useful in pharmaceutical compositions (wt %) of

This increase in intra-atomic N distance, which is most
likely a result of ion repulsion between the two cationic

the active ingredient with a carrier or vehicle in the com

centers, is equivalent to arotation of approximately 8° about
the C(3)-C(2') bond of the monocationic molecule.
The pKa for the n'-amino function of nicotine is 8.4,
calculated from after 1H-NMR. Therefore, a physiological
pH, nicotine exists predominantly (>95%) in the monoca
tionic n'-protonated species. However, in the case of the
three quaternary ammonium compounds described in Table
5, the pKa of the N'-amino group is two units lower than in
nicotine. This reduction in basicity of the pyrrolidino-N in
the antagonist molecules is due to the existing positive

istration either solid or ?uid unit dosage forms can be

position in about 1 to 20% and preferably about 5 to 15%.
Either ?uid or solid unit dosage forms can be readily
prepared for oral administration. For example, the com
pounds of the invention can be mixed with conventional
ingredients such as dicalciumphosphate, magnesium alumi
num silicate, magnesium stearate, calcium sulfate, starch,

talc, lactose, acacia, methyl cellulose and functionally simi
20

charge on the molecule and also due to the B-electron

withdrawing effect of the pyridinium moiety on the pyrro

25

lidino N-atom. These two factors would make it more

di?icult to protonate the N'-amino group. Thus, at physi

ological pH, the antagonist molecules will exist predomi
nantly in their unprotonated forms.
The nicotinic receptor pharmacophore incorporates a cat
ionic center (i.e., a protonated pyrrolidine-N of S(—)

sustained release formulation may optionally be used. Cap
sules may be formulated by mixing the compound with a
pharmaceutical diluent which is inert and inserting this
mixture into a hard gelatin capsule having the appropriate
size. If soft capsules are desired a slurry of the compound
with an acceptable vegetable, light petroleum, or other inert
oil can be encapsulated by machine into a gelatin capsule.
Suspensions, syrups and elixirs may be used for oral
administration of ?uid unit dosage forms. A ?uid preparation
including oil may be used for oil soluble forms. A vegetable
oil such as corn oil, peanut oil or safflower oil, for example,

together with ?avoring agents, sweeteners and any preser
vatives produces an acceptable ?uid preparation. A surfac

nicotine) and an electronegative atom that is able to partici
pate in a hydrogen-bond interaction with a receptor moiety

(i.e., the pyridino-N of S(—)nicotine. From the present data,
an antagonist binding mode for the quaternary ammonium
nicotine analogues is suggested. The pyridinium-N atom in
the antagonist molecules occupies the anionic site of the
nicotine receptor that normally accommodates the proto

lar materials as pharmaceutical excipients or carriers. A

tant may be added to water to form a syrup for ?uid unit
35

dosages. Hydro-alcoholic pharmaceutical preparations may
be used having an acceptable sweetener such as sugar,
saccharine or a biological sweetener and a ?avoring agent in
the form of an elixir.

nated pyrrolidino-N functionality of the agonist S(—)

Pharmaceutical compositions for parenteral and supposi

nicotine. The unprotonated pyrrolidino-N atom of the
antagonist then functions as the hydrogen-bond acceptor
moiety. Thus, compared to the two nitrogen atoms in the
nicotine molecule, the two nitrogen atoms in the antagonist
molecules have interchanged their roles when binding to the
nicotinic receptor, with a resulting change in activity from
agonist to antagonist (FIG. 4). The size of the pyridino-N
substituent is also an important factor governing antagonist

tory administration can also be obtained using techniques
standard in the art. The above parenteral solutions or sus

pensions may be administered transdermally and, if desired
a more concentrated slow release form may be administered.
45

e?icacy. This appears to indicate the presence of an addi

Accordingly, incorporation of the active compounds in a
slow release matrix may be implemented for administering
transdermally. The compounds may be administered trans
dermally at about 1 to 20% of the composition and prefer
ably about 5 to 15% wt % of the active ingredient in the

tional lipophilic binding site or pocket constituting another
important component of the antagonist pharmacophore. This
binding site extends beyond the normal agonist pharma
cophore volume. Thus, interaction of the antagonist with this
site may prevent the receptor protein from achieving the

vehicle or carrier.

open channel quaternary form.

peutic e?icacy, reduction in the frequency of dosing, reduc

Transdermal therapeutic systems are self-contained dos

age forms that, when applied to intact skin, deliver drug(s)
at a controlled rate to the systemic circulation. Advantages

of using the transdermal routing include: enhanced thera

In sum, this work has resulted in the emergence of a new 55 tion of side e?’ects due to optimization of the blood

concentration versus time pro?le, increased patient
compliance due to elimination of multiple dosing schedules,

class of e?icacious nicotinic antagonist which inhibit nico
tine evoked [1H]DA release from dopaminergic nerve ter
minals. These antagonists appear to interact with the nico
tinic receptor modulating dopamine release in a novel
binding mode and may serve as new tools for unraveling the

bypassing the hepatic “?rst-pass” metabolism, avoiding

complexities of neuronal nicotinic receptors.

function of the skin is to act as a barrier to entering

For the purpose of this invention, the racemic mixtures
and the dextro and levo forms are included within the

compounds. As a consequence, transdermal therapy has so
far been restricted to a limited number of drugs that possess

present invention. The racemic mixtures and the dextro
forms are preferred.
Further, the compounds of the present invention are useful

in pharmaceutical compositions for systemic administration

gastrointestinal incompatibilities and providing a predict
able and extended duration of activity. However, the main

65

the desirable physiochemical properties for diffusion across
the skin barrier. One e?ective method of overcoming the
barrier function of the skin is to include a penetration
enhancer in the formulation of a transdermal therapeutic
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system. See Barry, Brian W.: Dermatological Formulations:
Percutaneous Absorption (Dekker, New York, 1983);
Bronough et al, Percutaneous Absorption, Mechanisms

Methodology-Drug Delivery, (Marcel Dekker, New York,

or saline; condensation products of castor oil and ethylene
oxide combining about 30 to about 35 moles of ethylene
oxide per mole of castor oil; liquid acid; lower alkanols; oils
such as corn oil; peanut oil, sesame oil and the like, with

NY. 1985); and Monkhouse et al, Transdennal drug deliver

emulsi?ers such as mono- or di-glyceride of a fatty acid, or

problems and promises. Drug Dev. Ind. Pharm., 14,
183-209 (1988).

lene glycols; aqueous media in the presence of a suspending

a phosphatide, e.g., lecithin, and the like; glycols; polyalky

A penetration enhancer is a chemical compound that,
when included in a formulation, temporarily increases the
permeability of the skin to a drug allowing more of the drug
to be absorbed in a shorter period of time. Several different

agent, for example, sodium carboxymethylcellulose; sodium
alginate; poly(vinylpyrol idone); and the like, alone, or with
suitable dispensing agents such as lecithin; polyoxyethylene

types of penetration enhancers have been reported such as

such as preserving stabilizing, wetting, emulsifying agents

dimethylsulfoxide, n-decyl methyl sulfoxide, N,N

and the like together with the penetration enhancer of this
invention.
The eifective dosage for mammals may vary due to such
factors as age, weight activity level or condition of the
subject being treated. Typically, an effective dosage of a
compound according to the present invention is about 10 to

stearate; and the like. The carrier may also contain adjuvants

dimethylacetamide, N<Ni-dimethylformamide,
l-dodecylazacycloheptan-Z-one (Azone), propylene glycol,
ethanol, pyrrolidones such as N-methyl-2-pyrrolidone
(NMP) and surfactants. See Bronough et a1, supra, and
Stoughton et al, Azone: a New Non-toxic enhancer of

percutaneous penetration. Drug Dev. Inc. Pharm., 9,
725-744 (1983).

20

N-methyl-Z-pyrrolidone is a versatile solvent which is

400 mg when administered by either oral or rectal dose from
1 to 3 times daily. Preferably about 20 to about 200 mg are
administered orally or rectally 1 to 3 times a day for an adult

human. The required dose is considerably less when admin
istered parenterally, preferably about 10 to about 50 mg may

miscible with water, ethyl alcohol, ether, chloroform,
benzene, ethyl acetate and carbon disul?de.
N-methylpyrrolidone has been widely used as a solvent in

“M-Pyrol (N-methyl-2-pyrrolidone) Handboo ”, GAF

be administered intrarnuscularly or transdermally, 1 or 2
times a day for an adult human.
In sum the invention provides a compound of the follow

Corp., New York, 1972. It is currently used as a solubilizing

ing formula:

industrial processes such as petroleum re?ning, GAF Corp.:

25

agent in topical and parenteral veterinary pharmaceuticals
and is now under consideration for use in products intended

‘E,

for humans, Wells, D. A. et a1: Disposition and Metabolism

\ ‘0

of Double-Labeled [3H and 1“C] N-methyl-2-pyrrolidone in
the Rat. Drug Met. Disps., 16, 243-249 ( 1988). Animal and

I

human experiments have shown very little irritation or

] Xe

CH3

at‘

sensitization potential. Ames type assays and chronic expo
sure studies have not revealed any signi?cant toxicity, Wells

/

If

CH1—R
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et al, Mutagenicity and (brtotoxicity of N-methyl-2-p
[yn'olidone and 4-(methyl amino) Butanoic Acid in the
Salrnonella/microsome Assay. J. AppL T0x., 8, 135-139

wherein R=N-a]kyl or branched alkyl with 2-19 carbon

(1988). N-methylpyrrolidone has also been shown to be an

carbon atoms, and N-alkynyl or branched alkynyl with 2-19

e?ective penetration enhancer. Barry et al, Optimization and
Bioavailability of Topical Steroids: Penetration Enhancers
Under Occlusion. J. Inv. Derm., 82, 49-52 (1984); Akter et
al, Absorption Through human Skin of Ibuprofen and Flur
bip'ofen; Effect of Dose Variation, Deposited Drug Films,
Occlusion and the Penetration Enhancer N-methyl-2
pyrrolidone. J. Phamt. Phar-macol, 37, 27-37 (1984); Hole
gaard et al, Vesical Eifect on Topical Drug Delivery IV.

atoms, cycloalkyl, aralkyl, N-alkenyl or alkenyl with 2-19

carbon atoms; and X=C1_, Br“, 1“, H504‘, ‘AS0421 Com
pounds in which R is branched alkyl with 2-19 carbon atoms
or R is a cycloalkyl or aralkyl group are preferred. In

addition compounds wherein in X is I“, are also preferred.
More particularly compounds selected from the group
45

F?ect of N-methylpyrrolidone and Polar Lipids on Percu

taneous Transport Int. J. Pharm, 43, 233-240 (1988);
Sugibayashi et al, Effect of Several Penetration Enhancers

50

on the Percutaneous Absorption of Indomethacin in Hairless

consisting of S-N-hydroxyethyl nicotinium iodide
(NHENI), S-N-nbutyl nicotinium iodine (NnBNI), S-N
propyl nicotinium iodide (NPNI), S-N-benzyl nicotinium
bromide (NBNB), S-N-octylnicotinium iodide (NONI), and
S-N-allylnicotinium iodide (NANI) have been shown to
have preferred nicotinic receptor antagonist activity.
The compounds of the invention can be used in a method

Rat. Chem. Pharm. Bull, 36, 1519-1529 (1988); Bennett et

of antagonizing the nicotinic receptor comprising adminis

al, Optimization of Bioavailability of Topical Steroids: Non
occluded penetration Enhancers Under Thermodynamic
Control. J. Pharm. PharmacoL, 37, 298-304 (1985); Sasaki

pound.

tering a pharrnaceutically effective amount of the com
55

et al, Enhancing Effect of Pyrrolidone Derivatives on Trans

derman Drug Delivery. 1. lug. J. Phame, 44, 14-24 (1988);
lee et al, Toxicity of N-methyl-2-pyrrolidone (NMP):
Tetratogenic, Subchronic and Two-year Inhalation Studies,
Fund. AppL, Tox., 9, 222-235 (1987).

is given in parentheses.
FIG. 2. IC50 values for N-substituted analogues of
nicotine, nornicotine, and cotinine to inhibit nicotine-evoked
[3H]DA release from rat striatal slices. Inhibition produced

The above and other drugs can be present in the reservoir
alone or in combination form with pharmaceutical carriers.
The pharmaceutical carriers acceptable for the purpose of

by the classical nicotinic inhibitors, mecarnylamine (MEC)

this invention are the art known carriers that do not

adversely a?ect the drug, the host, or the material compris

DETAILED DESCRIPTION OF_ THE DRAWINGS
FIG. 1. Structures of S(-)nicotine and related compounds
studied in [3H]DA release assays. Abbreviated nomenclature

and DHBE was also detennined. Slices were superfused
65

with inhibitor for 60 min following co-superfusion with 10

ing the drug delivery device. Suitable pharmaceutical car

M nicotine. Inhibition was determined by comparing [3H]

riers include sterile water; saline, dextrose; dextrose in water

DA release in the absence and presence of various concen

5,691,365
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trations of inhibitor. IC50 values were determined using the

Grady 5., Marks M. J., Wonnacott S. and Collins A. C.

Legit-log plot (pseudo-Hill plot). The analogue-induced

(1992): Characterization of nicotinic receptor-mediated
[3H]doparnine release from synaptosomes prepared from

percentage of inhibition (P) of [3H]DA release evoked by
S(—)nicotine (10 M) was used to calculate log (P/[1-P]),
which Was plotted against the log concentration of analog.

mouse striatum. J. Neurochern. 59:848-856.

Grenhoif J. and Svensson T. H. (1989): Pharmacology of
nicotine. Br. J. Addict. 84:477-492, 1989.
Leutje C. W., Patrick J. and Séguéla P. (1990a): Nicotine
receptors in the mammalian brain. FASEB J.
422753-2760.

ICSO for each animal was determined as the intercept of the

linear regression. For each analogue, the IC50 was obtained
from the mean of the group of animals used for that
analogue. Structures of the N-substituted compounds are
given in FIG. 1.
FIG. 3. Space ?lling models of minimum energy con

10

Heinemann S. and Patrick J. (1990b): Neurotoxins dis

formers of N'-protonated S(—)nicotine and the unprotonated

tinglish between di?°erent neuronal nicotinic acetylcho

and protonated forms of NONI.
FIG. 4. Overlay of the minimum energy conformers of

protonated S(—)nicotine (red) and unprotonated S(—)NONI
(black) showing the comparable N-N intra-atomic distances
in these molecules and the hypothetical mode of binding at
the anionic site (A) and the hydrogen donor site (B) of the
nicotinic receptor.
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atoms, cycloalkyl, aralkyl, N-alkenyl or alkenyl with 2-19
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The purpose of the above description and examples is to
illustrate some embodiments of the present invention with
out implying any limitation. It will be apparent to those of
skill in the art that various modi?cations and variations may
be made to the composition and method of the present
inven?on without departing from the spirit or scope of the
invention. All patents and publications cited herein are

in need of said treatment.
9. A method of treatment of a condition selected from the

group consisting of abuse of nicotinic agonist drugs, smok
ing addiction, and nicotine intoxication comprising admin
istering a pharmaceutically e?tective amount of a compound

according to the following formula:
25

|
30

/

|

CH:

*1
CHz-R

incorporated by reference in their entireties.
We claim:

1. A compound of the following formula:

wherein R=N-alkyl or branched alkyl with 2-19 carbon
35

atoms, cycloalkyl, aralkyl, N-alkenyl or alkenyl with 2-19
carbon atoms, and N-alkynyl or branched alkynyl with 2-19
carbon atoms; and X=Cl_, Br‘, 1“, H804‘, VzSO42' to a host

I

/

in need of said treatment.
10. A method of treatment of Alzheimer’s disease com

|

CH3

prising administering a pharmaceutically e?ective amount
of a compound of the following formula:

“i
Cl’h-R
wherein R=branched alkyl with 4-19 carbon atoms,
cycloalkyl, N-alkenyl or alkenyl with 4-19 carbon atoms,
and N-alkynyl or branched alkynyl with 4-19 carbon atoms;

45

and X=Cl*, 1“, H804“, $68042“.
2. A compound according to claim 1, wherein in R is
branched alkyl with 4-19 carbon atoms.
3. A compound according to claim 1, wherein in X is I‘.
4. A compound according to claim 1, wherein said com
pound is selected from the group consisting of S-N

50

wherein R=N-a1kyl or branched alkyl with 2-19 carbon

atoms, cycloalkyl, aralkyl, N-alkenyl or alkenyl with 2-19

hydroxyethyl nicotinium iodide (NHENI), S-N-propyl nico
tinium iodide (NPNI), S-N-benzyl nicotinium bromide
(NBNB), S-N-octylnicotinium iodide (NONI), and S-N

55

carbon atoms, and N-alkynyl or branched alkynyl with 2-19
carbon atoms; and X=Cl_, Br‘, I‘, H804“, 1/2SO42_ to a host

allyl-nicotinium iodide (NANI).

in need of said treatment.

5. A compound according to claim 4, wherein said com
pound has an order of potency wherein

11. A compound according to claim 1 wherein said
compound competitively inhibits central nervous system

NONI>>MEC>>NPNI=NANI>NHENI>>>(i)di-N-allyl
nicotinium iodide (DNANI)=(i)N-methyl nornicotinium
iodide (NMNNI)=NMNI= S-N-methyl cotininium iodide

(NMCI)=S-N'-methy1 nicotinium iodide PIPNMN).
6. A compound according to claim 1, wherein said com
pound is a nicotinic receptor antagonist.
7. A compound according to claim 1, wherein said com

pound inhibits nicotine-evoked dopamine release.

acting nicotinic agonists.
12. A compound according to claim 11 wherein said
compound acts at the (13152 neuronal nicotinic receptor in the
central nervous system.
13. A method of treatment of Parkinson=’s disease com
65

prising administering a pharmaceutically effective amount
of a compound according to the following formula:

5,691,365
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wherein R=N-alkyl or branched alkyl with 2-19 carbon

atoms, cycloalkyl, aralkyl, N-alkenyl or alkenyl with 2-19
4-19 carbon atoms, and N-a]kynyl or branched alkynyl with

2-19 carbon atoms; and X=Cl_, Br‘, 1“, H504‘, ‘AS042’ to
S

a host in need of said treatment.

